BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36331823)

  • 1. Interplay of Atherogenic Particle Number and Particle Size and the Risk of Coronary Heart Disease.
    Pencina KM; Pencina MJ; Lawler PR; Engert JC; Dufresne L; Ridker PM; Thanassoulis G; Mora S; Sniderman AD
    Clin Chem; 2023 Jan; 69(1):48-55. PubMed ID: 36331823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.
    Pischon T; Girman CJ; Sacks FM; Rifai N; Stampfer MJ; Rimm EB
    Circulation; 2005 Nov; 112(22):3375-83. PubMed ID: 16316964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C.
    Pencina MJ; D'Agostino RB; Zdrojewski T; Williams K; Thanassoulis G; Furberg CD; Peterson ED; Vasan RS; Sniderman AD
    Eur J Prev Cardiol; 2015 Oct; 22(10):1321-7. PubMed ID: 25633587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of LDL-CT, non-HDL/HDL ratio, and ApoB/ApoA1 in assessing CHD risk among patients with type 2 diabetes mellitus.
    Păunică I; Mihai AD; Ștefan S; Pantea-Stoian A; Serafinceanu C
    J Diabetes Complications; 2023 Dec; 37(12):108634. PubMed ID: 37918178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study.
    Björnson E; Adiels M; Taskinen MR; Burgess S; Rawshani A; Borén J; Packard CJ
    Eur Heart J; 2023 Oct; 44(39):4186-4195. PubMed ID: 37358553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
    Ference BA; Kastelein JJP; Ray KK; Ginsberg HN; Chapman MJ; Packard CJ; Laufs U; Oliver-Williams C; Wood AM; Butterworth AS; Di Angelantonio E; Danesh J; Nicholls SJ; Bhatt DL; Sabatine MS; Catapano AL
    JAMA; 2019 Jan; 321(4):364-373. PubMed ID: 30694319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein B Displays Superior Predictive Value Than Other Lipids for Long-Term Prognosis in Coronary Atherosclerosis Patients and Particular Subpopulations: A Retrospective Study.
    Zhang C; Ni J; Chen Z
    Clin Ther; 2022 Aug; 44(8):1071-1092. PubMed ID: 35902283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sugar-Sweetened Beverage Consumption and Plasma Lipoprotein Cholesterol, Apolipoprotein, and Lipoprotein Particle Size Concentrations in US Adults.
    Haslam DE; Chasman DI; Peloso GM; Herman MA; Dupuis J; Lichtenstein AH; Smith CE; Ridker PM; Jacques PF; Mora S; McKeown NM
    J Nutr; 2022 Nov; 152(11):2534-2545. PubMed ID: 36774119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease.
    Dron JS; Patel AP; Zhang Y; Jurgens SJ; Maamari DJ; Wang M; Boerwinkle E; Morrison AC; de Vries PS; Fornage M; Hou L; Lloyd-Jones DM; Psaty BM; Tracy RP; Bis JC; Vasan RS; Levy D; Heard-Costa N; Rich SS; Guo X; Taylor KD; Gibbs RA; Rotter JI; Willer CJ; Oelsner EC; Moran AE; Peloso GM; Natarajan P; Khera AV
    JAMA Cardiol; 2023 Mar; 8(3):258-267. PubMed ID: 36723951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
    Ference BA; Kastelein JJP; Ginsberg HN; Chapman MJ; Nicholls SJ; Ray KK; Packard CJ; Laufs U; Brook RD; Oliver-Williams C; Butterworth AS; Danesh J; Smith GD; Catapano AL; Sabatine MS
    JAMA; 2017 Sep; 318(10):947-956. PubMed ID: 28846118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
    Ballantyne CM; Raichlen JS; Cain VA
    J Am Coll Cardiol; 2008 Aug; 52(8):626-32. PubMed ID: 18702965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid profile, lipid ratios, apolipoproteins, and risk of cardiometabolic multimorbidity in men: The Kuopio Ischaemic Heart Disease Risk Factor Study.
    Tajik B; Voutilainen A; Kauhanen J; Mazidi M; Lip GYH; Tuomainen TP; Isanejad M
    Lipids; 2022 Mar; 57(2):141-149. PubMed ID: 35049039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women.
    Ingelsson E; Schaefer EJ; Contois JH; McNamara JR; Sullivan L; Keyes MJ; Pencina MJ; Schoonmaker C; Wilson PW; D'Agostino RB; Vasan RS
    JAMA; 2007 Aug; 298(7):776-85. PubMed ID: 17699011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of apolipoprotein B to cholesterol in low density lipoproteins of patients with coronary heart disease.
    Vega GL; Grundy SM
    J Lipid Res; 1984 Jun; 25(6):580-92. PubMed ID: 6747462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis.
    Björnson E; Adiels M; Taskinen MR; Burgess S; Chapman MJ; Packard CJ; Borén J
    J Am Coll Cardiol; 2024 Jan; 83(3):385-395. PubMed ID: 38233012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LDL/apo B ratio predict coronary heart disease in Type 2 diabetes independent of ASCVD risk score: A case-cohort study.
    Rabizadeh S; Rajab A; Mechanick JI; Moosaie F; Rahimi Y; Nakhjavani M; Esteghamati A
    Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1477-1485. PubMed ID: 33810957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study.
    Schaefer EJ; Lamon-Fava S; Cohn SD; Schaefer MM; Ordovas JM; Castelli WP; Wilson PW
    J Lipid Res; 1994 May; 35(5):779-92. PubMed ID: 8071601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.
    Marston NA; Giugliano RP; Melloni GEM; Park JG; Morrill V; Blazing MA; Ference B; Stein E; Stroes ES; Braunwald E; Ellinor PT; Lubitz SA; Ruff CT; Sabatine MS
    JAMA Cardiol; 2022 Mar; 7(3):250-256. PubMed ID: 34773460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme gene polymorphism, lipids, and apolipoproteins in menopausal women on hormone replacement therapy.
    Cubrilo-Turek M; Sertić J; Duraković Z
    Acta Med Croatica; 2001; 55(4-5):161-7. PubMed ID: 12398019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of lipoprotein particle measures for assessing coronary heart disease risk post-American Heart Association/American College of Cardiology guidelines: the Multi-Ethnic Study of Atherosclerosis.
    Steffen BT; Guan W; Remaley AT; Paramsothy P; Heckbert SR; McClelland RL; Greenland P; Michos ED; Tsai MY
    Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):448-54. PubMed ID: 25477346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.